Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Z0063 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Sequence 1 (Z0063 to Gaviscon) | EXPERIMENTAL | The subjects will be given Z0063 single dose and then will crossover to Gaviscon single dose |
| Sequence 2 (Gaviscon to Z0063) | EXPERIMENTAL | The subjects will be given Gaviscon single dose and then will crossover to Z0063 single dose |
| Name | Type | Description |
|---|---|---|
| Z0063 | DRUG | Pharmaceutical form: chewable tablets Route of administration: oral |
| Gaviscon | DRUG | Pharmaceutical form: chewable tablets Route of administration: oral |
Inclusion criteria : * Male or female subjects, between 18 and 55 years of age, inclusive. * Body weight between 50.0 and 100.0 kg, inclusive, if male, and between 40.0 and 90.0 kg, inclusive, if female, body mass index between 18.0 and 28.0 kg/m2, inclusive. * Certified as healthy by a comprehensi...
Z0063 is an investigational small molecule being developed by Sanofi for Gastroesophageal Reflux Disease (GERD). It is currently in Phase 1 clinical development, with two completed trials in healthy adult subjects. Z0063 is not yet approved and remains under investigation for its potential antireflux and antacid activity.
Z0063 is being developed by Sanofi, a global biopharmaceutical company traded on the stock exchange under the ticker SNY. The drug is an investigational small molecule intended for the treatment of Gastroesophageal Reflux Disease and is currently in Phase 1 clinical trials.
Z0063 is in Phase 1 clinical development. Two Phase 1 trials have been completed, both enrolling healthy adult volunteers. The drug is investigational and has not been approved by regulatory authorities. Its safety and activity are being evaluated for Gastroesophageal Reflux Disease.
Z0063 has two completed Phase 1 trials. NCT03065816 compared its antireflux activity against Gaviscon Double Action tablets in 34 healthy adults in the United Kingdom. NCT03069963 compared its antacid activity against the same comparator in 24 healthy adults in France. Both studies enrolled participants aged 18 and older.
No, Z0063 is not the same as Gaviscon. Z0063 is an investigational drug being developed by Sanofi, while Gaviscon is a marketed antacid product. In clinical trials, Z0063 was compared against Gaviscon Double Action tablets to evaluate its antireflux and antacid activity in healthy volunteers.